000			03382nam a2200445 i 4500
999			_c361328 _d361328
001			361328
003			ES-MaUEC
005			20230102121344.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			211022s2021 sz | o |||| 0|eng d
020			_a9783030797904
024	7		_a10.1007/978-3-030-79790-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM332 _b2021 EB
245	0	0	_aNew Rapid-acting Antidepressants _cedited by Kenji Hashimoto, Mario Manto
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (VII, 149 páginas) _b14 ilustraciones, 9 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aContemporary Clinical Neuroscience _x2627-5341
490	0		_aBiomedical and Life Sciences (SpringerNature-11642)
490	0		_aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505	0		_a(R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
520	3		_aThis book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level.
988			_aSpringer_BiomedLife_2021
650		7	_2embne _9141495 _aAntidepresivos
650		7	_2embne _9139882 _aPsicofarmacología
700	1		_aHashimoto, Kenji _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9680809
700			_aManto, Mario _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _984532
776	0	8	_iPrinted edition: _z9783030797898
776	0	8	_iPrinted edition: _z9783030797911
776	0	8	_iPrinted edition: _z9783030797928
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-79790-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2022 _dz _eb _zSI